Mineralys Therapeutics, Inc.
MLYS
$-0.73
Change (1 day)
$16.91
Year High
$6.06
Year Low
Categories
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Earnings for Mineralys Therapeutics, Inc. (MLYS)
Earnings in 2023 (TTM): $-71,898,000
According to Mineralys Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $-71,898,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Mineralys Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-71,898,000 | $-71,898,000 |
| 2022 | $-29,799,000 | $-29,799,000 |
| 2021 | $-19,408,000 | $-19,408,000 |
| 2020 | $-3,426,000 | $-3,426,000 |